The national priority Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) trial is open at UHS and recruiting patients from ICU.

​

REMAP-CAP, led in Southampton by PI Dr Ahilanadan Dushianthan, is a multi-centre international adaptive platform trial of critically ill patients with community acquired pneumonia, including COVID-19.

​

It has multiple domains to evaluate multiple interventions simultaneously, including antivirals and immunomodulators, and will also evaluate potential interactions. 

​

You can find out more about the study at www.remapcap.org/coronavirus.

​

Please email Ahilanadan.Dushianthan@uhs.nhs.uk for more information.